Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Pick a strategy above and run the backtest to see its simulated performance on PCRX.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
Pacira BioSciences stock (PCRX) sits at $25.20, up 1.78% today. The business is worth $1.00B in the market, good for #3237 of 3753 on our coverage list.
Over a full year the shares have ranged across $18.80 to $27.66, which puts the current price roughly 72% of the way up that band. Holders are ahead 7.6% over twelve months, but down 1.2% across the last three months.
On the chart it holds above both the 50-day ($25.18) and 200-day ($23.88) moving averages; RSI is 51, and the last 30 sessions moved at roughly 28% annualized volatility.
In the quarter ended Jun 2026 the company brought in $192.40M of revenue, up 6.2% from a year earlier, with $4.65M of net profit (a 2.0% margin).
Valuation works out to 72.0 times trailing earnings, 160% above its five-year average of 27.7. The median for its industry group is 22.0.
7 analysts follow the stock and the average call is "buy". The mean target, $30.00, sits 19.0% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 3752 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
7 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
PCRX is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $30.00, 19.0% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $32.68, so shares trade 22.9% below that estimate. On earnings multiple, it sits in the 68th percentile of its own five-year valuation range (pricier than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +1.0% | Bullish |
| Price vs 50-day average | +0.1% | Bullish |
| Price vs 200-day average | +5.5% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 50.9 | Bullish |
| MACD (12,26,9) | -0.03 | Bullish |
| Bollinger band position | 65% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 8, 2026 8:10 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,752 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 72.0x earnings, PCRX looks expensive against the market, and trades 227% above the 22.0x median among Drug Manufacturers - Specialty & Generic names. The two comparisons do not always agree.
$25.20 is the latest print for PCRX, a move of +1.78% against yesterday's close of $24.76. Today's low and high so far: $24.99 and $26.00.
Equity value comes to $1.00B at the current price. By that measure it is number 3237 of the 3753 names in our coverage.
Buyers pay 72.0 times the last twelve months of profit (EPS $0.16). Averaged over five years the multiple has been 27.7, and today's level ranks in the 68th percentile of its own history.
The year's floor is $18.80 and the ceiling $27.66. Shares are 8.9% away from that ceiling.
Our data shows no dividend paid by Pacira BioSciences over the trailing twelve months.
Of 7 analysts, 57% say buy, 29% hold and 14% sell. Price targets average $30.00, with the most cautious at $23.00 and the most optimistic at $38.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on PCRX.